AKT1 and triple-negative breast carcinoma: Finally, it has also been shown that the JAK/STAT3/MAPK/Akt pathway, which is modulated by the expression of ERα36 [44], is involved in the resistance of MDA-MB 231 and MDA-MB 468 triple negative breast cancer cells to paclitaxel [108].